CTL019 Out of Specification MAP for ALL or DLBCL Patients
Available
Sponsor: Novartis Pharmaceuticals
Collaborators:
Information provided by (Responsible party):
Sponsor
ClinicalTrials.gov Identifier: NCT03601442
Protocol Info
Short Description: |
CTL019 Out of Specification MAP for ALL or DLBCL Patients |
Long Description: |
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of
specification for commercial release |
MGH Status: |
Open |
Sponsor: |
Novartis |
Disease Program: |
Cellular |
Next Steps
If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.
Purpose
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia
(ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification
leukapheresis product and/or manufactured tisagenlecleucel out of specification for
commercial release.
Condition Title |
Intervention |
Phase |
Acute Lymphoblastic Leukemia (ALL)
Diffuse Large B-cell Lymphoma (DLBCL)
|
CTL019
|
|
Study Type |
Expanded Access |
Official Title |
Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release |
Primary Outcome Measures
Secondary Outcome Measures
Estimated Enrollment: |
|
Study Start Date: |
|
Estimated Study Completion Date: |
|
Estimated Primary Completion Date: |
|
Eligibility
Ages Eligible for Study: 25 Years-25 Years
Genders Eligible for Study: All
Accepts Healthly Volunteers: No
Inclusion Criteria:
- • Written informed consent must be obtained prior to any screening procedures or
treatment assignment.
- • Has a patient specific batch of CTL019 which is out of specification either due to out
of specification incoming apheresis or final product not meeting commercial release.
- • Not excluded from commercial manufacturing under the prescribing guidelines for their
country
- • Out of specification material has not been deemed to pose an undue safety risk to the
patient
- • Is suffering from a serious or life-threatening disease or condition
- • Repeat leukapheresis is not feasible per the treating physician assessment
- • Does not have access to a comparable or satisfactory alternative treatment
- • Is not eligible for participation in any of the IMP's ongoing clinical trials or has
recently completed a clinical trial that has been terminated and, after considering
other options, the clinical team has determined that treatment is necessary and there
are no other feasible alternatives for the patient
- • Meets any other relevant medical criteria for compassionate use of the investigational
product
- • Is not being transferred from an ongoing clinical trial for which they are still
eligible
Exclusion Criteria:
- • Product can be commercially manufactured per the specification of the country in which
treatment will occur.
- • Patients who are able to repeat leukapheresis.
- • Evidence of CD19 negative disease
- • HIV positive patients
- • Patients with active replication of Hep B or active or latent Hep C
- • History of hypersensitivity to any drugs or metabolites of similar chemical classes as
tisagenlecleucel.
- • Uncontrolled active infection or inflammation
- • History of unstable angina or MI within 6 months prior to screening
- • Any medical condition identified by the investigator that may impact the assessment of
the safety or efficacy outcomes in relation to study treatment
More Information
No publications provided
Responsible Party: |
Sponsor
|
ClinicalTrials.gov Identifier: |
NCT03601442 |
Other Study ID Numbers: |
|
Study First Received: |
|
Last Updated: |
|
Health Authority: |
|
Keywords provided by Novartis:
Acute Lymphoblastic Leukemia
ALL
Pediatric
Diffuse Large b-cell Lymphoma
DLBCL
Adult
Relapse
Refractory
CTL019
tisagenlecleucel
Kymriah
CART19
CART
CAR T cells
Chimeric antigen receptor
Manufacturing
Expanded Access
Out of Specification
Additional relevant MeSH terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Next Steps
If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.
ClinicalTrials.gov processed this data on January 14, 2021